News

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...
The Food and Drug Administration is revising the labeling of all extended-release stimulants used to treat attention-deficit ...
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...
Study analyzing 77 research papers finds habitual consumption of processed foods increases chronic disease risk, challenging ...
The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...